TSC

Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Martedì, Marzo 7, 2023
Biotechnology, Finance, Health, Professional Services, Pharmaceutical, RSE, Office of Inspector General, U.S. Department of Health and Human Services, IV, Security (finance), Development, Therapy, EMA, European Medicines Agency, Ganaxolone, CDKL5 deficiency disorder, Patent, Human services, Growth, SG, Status epilepticus, CDD, Administration, Medicaid, Eugnosta tenacia, Epilepsy, BARDA, GAAP, Patient, Biomedical Advanced Research and Development Authority, ESE, TSC, Medication, CDKL5, Administration for Strategic Preparedness and Response, CV, U.S. Department of Defense Strategy for Operating in Cyberspace, R, Research, Forest Law Enforcement and Governance Program, Pharmaceutical industry, Nursing, Vaccine, Cryptocurrency, RAISE

Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2022.

Key Points: 
  • Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2022.
  • “2022 was a year of significant growth and execution for Marinus, underscored by the successful U.S. launch of ZTALMY,” said Scott Braunstein, M.D., Chairman and Chief Executive Officer of Marinus.
  • Recognized $2.3 million and $2.9 million in net product revenues for the three and twelve months ended December 31, 2022, respectively.
  • Recognized collaboration revenue of $3.0 million in the fourth quarter of 2022 related to the upfront payment associated with the Company’s development and commercialization agreement with Tenacia.

HealthRecon Connect Successfully Attains SOC 2® Type 2 Certification

Retrieved on: 
Venerdì, Marzo 3, 2023
American Institute, System, Content as a service, American Institute of Certified Public Accountants, AICPA, Quality management system, Information, TSC, Certified Public Accountant, ISO, ISO 27001:2013, HIPAA, Confidentiality, SOC, Information security management, Audit

DALLAS, March 03, 2023 (GLOBE NEWSWIRE) -- HealthRecon Connect, a leading technology enabled revenue cycle management solutions provider to US Healthcare Providers, reaffirmed its commitment to maintaining high standards of service delivery and internal security controls by successfully completing the System and Organizational Controls SOC 2® Type 2 audit.

Key Points: 
  • DALLAS, March 03, 2023 (GLOBE NEWSWIRE) -- HealthRecon Connect, a leading technology enabled revenue cycle management solutions provider to US Healthcare Providers, reaffirmed its commitment to maintaining high standards of service delivery and internal security controls by successfully completing the System and Organizational Controls SOC 2® Type 2 audit.
  • A widely recognized auditing standard developed by the American Institute of Certified Public Accountants (AICPA), the SOC 2® audits assess the security, availability, processing integrity, confidentiality and privacy controls in service organizations against the AICPA’s Trust Services Criteria (TSC).
  • “Obtaining the SOC 2® certification reaffirms our commitment to providing our clientele and stakeholders the highest level of internal controls and security” – Denver Fernando, CEO of HealthRecon Connect.
  • The successful completion of the SOC 2® Type 2 certification complements the organization’s recent achievement of being awarded the SOC 2® Type 1 and SOC 1® Type 1 and 2 certifications, the ISO 9001:2015 (Quality Management Systems), ISO 27001:2013 (Information Security Management) and ISO 27701:2019 (Privacy Information Management Systems) certifications and the seal of Compliance from the Compliancy Group, the recognized third-party HIPAA compliance verification standard for healthcare professionals, vendors, and IT professionals across the healthcare industry.

TSC Alliance® to Present 22nd Annual Comedy for a Cure® on April 2

Retrieved on: 
Giovedì, Marzo 2, 2023
Courage, DSM-IV codes, Comedy, Russell Peters, Ramesh, Avalon Hollywood, Jazz Pharmaceuticals, Research, Neoplasm, Last Comic Standing (season 4), Ovation, Global Leadership Awards, Investment, Cure, Movement disorder, Maginn, Disease, Lesley, TSC, NBC, Film industry, Pharmaceutical industry, Entertainment, Epilepsy

LOS ANGELES, March 2, 2023 /PRNewswire/ -- Today, the TSC Alliance® announced its 22nd Annual Comedy for a Cure® will be held Sunday, April 2, at AVALON Hollywood. The event brings together top comedians and entertainers to raise funds for those impacted by tuberous sclerosis complex (TSC), a rare genetic disease that causes tumors to form in vital organs.

Key Points: 
  • LOS ANGELES, March 2, 2023 /PRNewswire/ -- Today, the TSC Alliance ® announced its 22nd Annual Comedy for a Cure ® will be held Sunday, April 2, at AVALON Hollywood .
  • "Since its inception, the TSC Alliance's national signature event, Comedy for a Cure, has raised more than $5.5 million toward finding a cure for TSC while improving the lives of those affected," said Kari Luther Rosbeck, President & CEO.
  • We are proud to support the TSC Alliance's Comedy for a Cure, which emphasizes this mindset shared by Jazz."
  • Comedy for a Cure also provides a platform to highlight and pay tribute to those who have made an impact in the fight against TSC.

TSC Printronix Auto ID Launches the PEX-2000 Print Engine - Capable of Printing and Encoding RFID Labels

Retrieved on: 
Martedì, Febbraio 28, 2023
ID, Channel, Software, RFID, Orientation, Calibration, TSC, Cassette tape, Video game

BREA, Calif., Feb. 28, 2023 /PRNewswire-PRWeb/ -- TSC Printronix Auto ID, a global leader in innovative thermal label printing solutions, announces the launch of its new 6-inch PEX-2000 Print Engine for automatic labeling. The PEX-2000 Print Engine was designed to easily integrate into any print and apply system and is engineered to keep production lines moving 24/7. Rugged, fast-paced, and easy-to-integrate the PEX-2000 is ideal for manufacturing and logistics applications where high-speed and high demand label printing is required.

Key Points: 
  • TSC Printronix Auto ID, a global leader in innovative thermal label printing solutions, announces the launch of its new 6-inch PEX-2000 Print Engine for automatic labeling.
  • The PEX-2000 Print Engine was designed to easily integrate into any print and apply system and is engineered to keep production lines moving 24/7.
  • BREA, Calif., Feb. 28, 2023 /PRNewswire-PRWeb/ -- TSC Printronix Auto ID, a global leader in innovative thermal label printing solutions, announces the launch of its new 6-inch PEX-2000 Print Engine for automatic labeling.
  • The PEX-2000 Print Engine was designed to easily integrate into any print and apply system and is engineered to keep production lines moving 24/7.

AM Best Affirms Credit Ratings of Sveriges Ångfartygs Assurans Förening (The Swedish Club)

Retrieved on: 
Venerdì, Gennaio 27, 2023
Banking, Professional Services, Insurance, Finance, Bank statement, Credit, AM, Sveriges Riksbank, News, AM Best, USD, Policy, ALL, Risk management, International Marxist Group, Swedish Club of Chicago, TSC, Club, P&I, Cryptocurrency

AM Best has affirmed the Financial Strength Rating of A- (Excellent) and the Long-Term Issuer Credit Rating of “a-” (Excellent) of Sveriges Ångfartygs Assurans Förening (The Swedish Club) (TSC or the Club) (Sweden).

Key Points: 
  • AM Best has affirmed the Financial Strength Rating of A- (Excellent) and the Long-Term Issuer Credit Rating of “a-” (Excellent) of Sveriges Ångfartygs Assurans Förening (The Swedish Club) (TSC or the Club) (Sweden).
  • The outlook of these Credit Ratings (ratings) is negative.
  • For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best’s Credit Ratings .
  • For information on the proper use of Best’s Credit Ratings, Best’s Performance Assessments, Best’s Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best’s Ratings & Assessments .

Capital Rx Earns Surescripts® Certification & SOC 2 Type 2 Report

Retrieved on: 
Venerdì, Febbraio 10, 2023
Streamlining Claims Processing for Federal Contractor Employees Act, Surescripts, Security, Workflow, Prescription, Patient, Change management, Privacy, EHR, Partnership, AICPA, HTTPS, Tetraplegia, SOC, Cos, Formulary, TSC, Logical security, Payment, Cryptocurrency, Health insurance

Additionally, Capital Rx completed its SOC 2 Type 2 report for JUDI® , the industry's first cloud-native enterprise pharmacy platform, and its Claims Processing Services (as of June 30, 2022).

Key Points: 
  • Additionally, Capital Rx completed its SOC 2 Type 2 report for JUDI® , the industry's first cloud-native enterprise pharmacy platform, and its Claims Processing Services (as of June 30, 2022).
  • "Leveraging JUDI's open architecture, we can deliver the same 100% accurate information in the Capital Rx member app to prescribers."
  • The Surescripts certification received by Capital Rx is for Surescripts Real-Time Prescription Benefit and Connectivity direct to Surescripts via HTTPS.
  • Capital Rx has engaged with a third-party auditor to perform its SOC 1 Type 2, SOC 2 Type 2, and SOC 3 engagements in 2023 and beyond.

Jazz Pharmaceuticals receives NICE recommendation for the reimbursement of Epidyolex® (cannabidiol) for the treatment of seizures associated with tuberous sclerosis complex in England

Retrieved on: 
Martedì, Gennaio 31, 2023
Newton, Dravet syndrome, Tuberous sclerosis, TSA, Heart, Jazz Pharmaceuticals, EMA, GW, Strategic planning, Medicines and Healthcare products Regulatory Agency, Seizure, NHS, Medicine, Skin, TSC, Epilepsy, Lennox–Gastaut syndrome, Cannabidiol, NICE, Wales, GW Pharmaceuticals, Brain, MHRA, Patient, National Institute for Health and Care Excellence, Ann Mercy Hunt, Clobazam, Healthcare Improvement Scotland, European Medicines Agency, Pharmaceutical industry

TSC can be diagnosed in infancy but many children are not diagnosed until later in childhood when their seizures begin and other symptoms appear.

Key Points: 
  • TSC can be diagnosed in infancy but many children are not diagnosed until later in childhood when their seizures begin and other symptoms appear.
  • [4] It is estimated that between 3,700 and 11,000 people in the UK live with TSC.
  • TSC is a very difficult to manage condition, with common issues including epilepsy in eight out of ten people.
  • Please note that, in relation to this Jazz media announcement, no honorarium was provided to the Tuberous Sclerosis Association.

TSC Printronix Auto ID Appoints James Cirigliano as VP of Marketing and Communications

Retrieved on: 
Giovedì, Gennaio 26, 2023
Cirigliano, Marketing, Knowledge, TSC, Communication, AIDC, Growth, DLS, Acquisition, Family, Printing, History, ID, Book

BREA, Calif., Jan. 26, 2023 /PRNewswire-PRWeb/ -- TSC Printronix Auto ID, a leading manufacturer of thermal barcode printing solutions, has announced that James Cirigliano has been appointed Vice President of Marketing and Communications.

Key Points: 
  • TSC Printronix Auto ID, a leading manufacturer of thermal barcode printing solutions, has announced that James Cirigliano has been appointed Vice President of Marketing and Communications.
  • BREA, Calif., Jan. 26, 2023 /PRNewswire-PRWeb/ -- TSC Printronix Auto ID, a leading manufacturer of thermal barcode printing solutions, has announced that James Cirigliano has been appointed Vice President of Marketing and Communications.
  • In his new role, he will oversee marketing and communication for TSC Printronix Auto ID, Americas.
  • "James will play a pivotal role in expanding TSC's internal and external communications, building upon the work of our dynamic communications team."

SoundCommerce Completes SOC II Type 2 Certification

Retrieved on: 
Lunedì, Gennaio 23, 2023
SOC, Confidentiality, TSC, American Institute, Certified Public Accountant, American Institute of Certified Public Accountants, AICPA, Type 2, SOC 2, Audit

SEATTLE, Jan. 23, 2023 /PRNewswire/ -- SoundCommerce, the leading retail data and analytics cloud platform, announced today that it has successfully completed the formal audit process for Service Organization Control (SOC) 2 Type II certification. Successful completion of the SOC 2 Type II audit further validates SoundCommerce's focus on data security and compliance and demonstrates a significant data operations milestone for the company.

Key Points: 
  • SEATTLE, Jan. 23, 2023 /PRNewswire/ -- SoundCommerce , the leading retail data and analytics cloud platform, announced today that it has successfully completed the formal audit process for Service Organization Control (SOC) 2 Type II certification.
  • Successful completion of the SOC 2 Type II audit further validates SoundCommerce's focus on data security and compliance and demonstrates a significant data operations milestone for the company.
  • "The security, integrity, and accessibility of business data is SoundCommerce's highest priority," said Eric Best, CEO SoundCommerce.
  • "Achieving SOC 2, Type 2 compliance ensures that SoundCommerce securely and comprehensively manages data and data processes to protect the interests of our customers."

Rare Disease, Facial Angiofibroma Associated with Tuberous Sclerosis Complex (TSC), is Focus of New Disease Education Website Launched by Nobelpharma America

Retrieved on: 
Martedì, Gennaio 17, 2023
Disease, Seizure, TSC, Brain, Kidney disease, Caregiver, Heart, Red, Skin, Bleeding, FACE, Autism, Social isolation, Central nervous system, Itch, Behavioral Problems, Nose, Chin, Beauty salon, Cosmetics

FACE FORWARD, a new website focused on disease awareness, has launched with educational content on facial angiofibroma, an aspect of tuberous sclerosis complex (TSC).

Key Points: 
  • FACE FORWARD, a new website focused on disease awareness, has launched with educational content on facial angiofibroma, an aspect of tuberous sclerosis complex (TSC).
  • FACE FORWARD also features background information about facial angiofibroma and TSC and a zip-code based tool that may help to locate certain treatment centers in the U.S.
  • Stories from people with facial angiofibroma and their caregivers are also offered on the site, aspiring to provide insights into living with facial angiofibroma associated with TSC.
  • BETHESDA, Md., Jan. 17, 2023 /PRNewswire/ -- Facial angiofibroma, an aspect of a rare genetic disease called tuberous sclerosis complex (TSC), is the focus of a new online resource, FACE FORWARD , launched by Nobelpharma America, LLC , a pharmaceutical and medical device company headquartered in Bethesda, Maryland.